Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Open-label Study in Adults to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19

Next Previous
X
Search
Trial Profile

A Phase III Open-label Study in Adults to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 08 Oct 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 1222 (Primary)
  • Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
  • Focus Adverse reactions; Registrational
  • Sponsors AstraZeneca

    • Most Recent Events

    • 27 Sep 2021 Planned End Date changed from 11 May 2021 to 11 May 2022.
    • 27 Sep 2021 Planned primary completion date changed from 11 May 2021 to 4 Dec 2020.
    • 27 Sep 2021 Status changed from suspended to withdrawn prior to enrolment due to The study was put on hold in September 2020 due to a safety concern in another trial but neverrestarted. In the meantime our clinical development program now includes a similar study with adifferent design, which we prefer to complete now. .

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top